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The Association Between Cytomegalovirus 
Infection and Cardiac Allograft Vasculopathy in 
the Era of Antiviral Valganciclovir Prophylaxis
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INTRODUCTION
Cardiac allograft vasculopathy (CAV) is a form of coro-
nary atherosclerosis in heart transplant (HTx) patients 
characterized by progression of intimal hyperplasia, which 
leads to diffuse narrowing of coronary arteries and is usu-
ally clinically silent because of allograft denervation.1,2 
Although the dynamics of its development are usually 
slow, in some patients, a rapid progression to occlusive 
disease within months is observed.3 With no effective 
etiological treatment strategy established to date, CAV is 
an independent predictor of major cardiovascular events 
in this population and one of the main factors that com-
promise long-term patient survival after HTx.4-6
Available evidence indicates that CAV results from an 
interplay between various immunologic and metabolic risk 
factors that include acute cellular and antibody-mediated 
rejection, anti-HLA and antiendothelial antibodies, older 
age and male sex of the donor (D), hyperlipidemia, insulin 
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CMV infection on the risk of CAV was seen only among HTx recipients with CMV breakthrough infection.
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resistance, and endothelial dysfunction. Some research-
ers report on the involvement of cytomegalovirus (CMV) 
disease or even subclinical CMV replication in the devel-
opment of CAV.5 Potential mechanisms of damage caused 
by CMV are direct endothelial assault and impairment of 
proper vascular remodeling.7 However, until now, clinical 
studies on the association between CMV and CAV yielded 
conflicting results.8-10 Moreover, over the recent decades, 
we observed major changes in both D and recipient (R) 
characteristics (a 33% prevalence of Ds aged >50 y, more 
stroke‐related Ds with a higher burden of atherosclerotic 
cardiovascular disease and higher proportion of Rs aged 
>60 y) but also modifications in post-HTx treatment (early 
statin treatment) and surveillance.11 In 2000, treatment 
with mycophenolate mofetil (MMF) was introduced, and 
international consensus guidelines on anti-CMV prophy-
laxis have been issued in the following years.12 There is 
a gap in evidence on to what extent these changes influ-
enced the prevalence of CAV in HTx Rs because previous 
studies on adult Rs included only patients transplanted 
before 2002.8,9,13,14 Therefore, the aim of this study was to 
evaluate the impact of CMV infection on prevalence and 
outcome of CAV in a cohort of HTx Rs treated according 
to current immunosuppressive and antiviral prophylactic 
regimens.
PATIENTS AND METHODS
Patient Cohort
All the adult patients who underwent HTx at our insti-
tution between January 2000 and May 2018 were screened 
for eligibility for the study. Second heart transplant was 
regarded as exclusion criterion unless it was performed 
because of primary graft failure early in the perioperative 
period. Those patients who did not survive until successful 
discharge after the surgery were excluded from the study. 
All patients received pravastatin 10 mg and aspirin 80 mg 
daily starting within 2–4 weeks posttransplant. Pravastatin 
dose was uptitrated gradually to 40 mg at 1-year post-HTx.
This study was approved by the local Ethical Committee 
of Erasmus MC (MEC-2017-421). The data were derived 
from the patients’ medical records and local registries 
according to the standards set by the Declaration of 
Helsinki.
Rejection Surveillance and Immunosuppressive 
Therapy
Rejection surveillance was performed by routine endo-
myocardial biopsy (EMB) of median (interquartile range 
[IQR]) 16 (14–18) times (during the first year after trans-
plantation and at 4 y post-HTx). After that period, EMBs 
were only taken when rejection was suspected. All patients 
included presented for routine EMB. Grading of the his-
tological findings was done according to International 
Society for Heart and Lung Transplantation (ISHLT) 
standards.
Several regimens of induction therapy (intravenous anti‐
T‐cell antibodies immediately after transplantation) have 
been used over time (Table S1, SDC, http://links.lww.com/
TP/B827). From 2000, the maintenance immunosuppres-
sion therapy changed from cyclosporine-based to a tacroli-
mus‐based scheme combined with prednisone and MMF. 
The standard dose of MMF used at our institution is from 
2 × 750 mg/d (if combined with tacrolimus) up to 2 × 
1500 mg/d (if combined with cyclosporin), modified based 
on trough level (optimum 1–3 mg/L). Either MMF or pred-
nisone was stopped at 1-year posttransplant depending on 
the amount of rejections and on the side effects of these 
drugs (eg, infections, diabetes mellitus, obesity). Acute cel-
lular rejection episodes were treated with pulsed high-dose 
methylprednisolone; in the case of steroid-resistant rejec-
tion, rabbit antithymocyte globulin was used. Antibody-
mediated rejection was treated only in case of signs of 
graft failure in combination with histological and immu-
nopathologic findings.
Coronary Allograft Vasculopathy Definition and 
Diagnosis
The diagnosis of CAV was based on coronary angiogra-
phy results and grading was applied according to ISHLT 
criteria published in 2010.15 Patients underwent routine 
CAV screening according to the protocol established at our 
institution: coronary angiography at 1 and 4 years after 
HTx unless contraindicated or patient refused. After 4 
years, coronary angiography was performed when clini-
cally indicated or significant abnormalities on annual sur-
veillance myocardial perfusion imaging.11 No patients 
missed the annual myocardial perfusion imaging.
CMV Prophylaxis and Screening Protocol
CMV prophylaxis and screening protocol are presented 
in Figure 1. Only CMV seronegative patients that received 
an organ from a seropositive D (D+/R−) received prophy-
laxis against CMV infection. Since 2000, there were 3 types 
of anti-CMV prophylactic regimes. Until October 2003, 
patients received human CMV immunoglobulin (CMVIG) 
(Megalotect CP, Biotest) on day 0, 7, 14, 28, 42, 56, and 
70 posttransplant. Between November 2003 and October 
2013, a standard of 3 months valganciclovir (VGCV) 
prophylaxis was given. After October 2013, 6 months 
VGCV prophylaxis was applied routinely. Prophylaxis 
with VGCV started at a standard dose of 450 mg/d from 
day 5 to 7 postoperatively (adjusted for renal function 
when necessary).
Screening for plasma CMV DNAemia was performed 
with quantitative real-time polymerase chain reaction 
(PCR) weekly for the first 6 weeks after HTx, then every 2 
weeks until the end of third-month post-HTx, then every 
2 months until the end of first-year post-HTx. With CMV 
seropositive Rs, there was no routine follow-up, that is, 
CMV PCR was performed only if CMV disease was sus-
pected. Besides pre-HTx CMV serostatus evaluation, 
CMV serology was not applied for the diagnosis of CMV. 
CMV prophylaxis together with immunosuppressive regi-
mens is summarized in Table S1 (SDC, http://links.lww.
com/TP/B827).
CMV Definitions
Clinically relevant CMV infection was defined as either 
plasma CMV DNAemia ≥1000 IU/mL independently 
of the presence of symptoms and signs or plasma CMV 
DNAemia <1000 IU/mL if accompanied with symptoms 
or signs that were typical for CMV disease (eg, fever, gas-
trointestinal disease, leukopenia, abnormal liver function 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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tests).16 The reason for choosing this definition was that 
we aimed to investigate only clinically relevant infection 
instead of asymptomatic CMV replication, which may be 
temporarily observed during infections caused by other 
pathogens or in any severe disease. The VGCV preemp-
tive treatment of asymptomatic CMV infection was 
started if plasma CMV DNAemia exceeded 1000 IU/mL. 
Breakthrough CMV infection was defined as the detec-
tion of CMV DNA in plasma by PCR while the patient 
was still receiving VGCV prophylaxis (regardless of CMV 
DNAemia level and symptoms). Additionally, we have 
evaluated any CMV infection defined as the detection 
of CMV DNA in plasma independent of the presence of 
symptoms and plasma CMV DNAemia level, which will 
be referred to as “CMV infection.”
CMV Monitoring
Plasma CMV DNAemia was monitored using a dual-
target, laboratory developed, quantitative real-time PCR 
(see Text S1 and Table S2, SDC, http://links.lww.com/
TP/B827). Results are reported in international unit per 
milliliter. All data generated before December 2012, 
were obtained with a different protocol, described previ-
ously17,18 and reported in copies/mL. These test results 
were converted to IU/mL using a conversion factor of 2, 
as was established during validation of the dual-target 
assay. The limit of quantification was 100 IU/mL before 
and 50 IU/mL after December 2012. All virological tests 
were performed in an International Organization for 
Standardization 15189:2012 accredited (or equivalent) 
clinical diagnostic setting.
CMV Treatment
Asymptomatic CMV infection with plasma CMV 
DNAemia ≥1000 IU/mL was treated with VGCV for at 
least 14 days until negative CMV PCR results in 2 con-
secutive plasma samples. Symptomatic CMV infection was 
treated for at least 14 days until disappearance of symp-
toms, and negative CMV PCR results in 2 consecutive 
plasma samples. Preferably, the MMF dose was halved or 
temporarily halted during preemptive treatment of CMV 
and during treatment of CMV disease. If there was a con-
firmed CMV resistance against VGCV, treatment with 
intravenous foscarnet was commenced.
Statistical Analysis
Distributions of continuous variables were tested for 
normality using the Shapiro-Wilk test. Normally distrib-
uted continuous variables are presented as mean and SD, 
nonnormally distributed continuous variables as median 
and IQR. Categorical data are displayed as count and per-
centage. In case of skewed distributions, continuous vari-
ables were logarithmically transformed (log base 2) for 
further analyses.
The primary endpoint analyzed was the combined end-
point, which comprised first manifestation of CAV grade 
1 or higher according to ISHLT 2010 nomenclature,15 
elective percutaneous coronary intervention or acute coro-
nary syndrome, or CAV-associated death. Death caused by 
other causes was regarded as competing risk. We evalu-
ated the associations between clinical characteristics and 
the primary endpoint by calculating cause-specific hazard 
ratios within Cox proportional hazards regression mod-
els. Clinically relevant CMV infection, CMV infection, 
and CMV breakthrough infection were entered as time-
dependent variables into these models. First, we performed 
univariable analyses. After that we performed a multi-
variable analysis with CMV breakthrough infection as 
time-dependent covariate and all the covariates that were 
significant by univariable analysis at a significance level of 
P < 0.05. We did not include the effect of recurrent CMV 
infection in the analysis. For the variables associated with 
rejection, we chose one (episodes of acute cellular rejection 
≥2 R/AMR) to avoid collinearity.
RESULTS
In total, 260 patients were included in the analysis. 
Among them, 3 patients received a second heart transplant. 
No patient was lost to follow-up. Median follow-up was 
7.9 (4.2–12.0) years, with 218 (84%) patients having at 
least 4 years of follow-up completed. Characteristics of the 
study population are presented in Table 1. CMV mismatch 
(D+/R−) was present in 71 (27%) patients. CMV serologi-
cal status at transplantation is presented in Figure 2. All 
the D+/R− patients received prophylaxis with CMVIG 
(n = 14; 20%) before 2003 and with VGCV (n = 57; 80%) 
after 2003. Over the follow-up, clinically relevant CMV 
infection was diagnosed in 96 (37%) patients. In CMV 
mismatch patients, clinically relevant CMV infection was 
more frequent than in the rest of the Rs (44 of 71 patients, 
62% versus 52 of 189 patients, 27%, P < 0.001), but it 
occurred at a later time point from HTx (138 [57–226] ver-
sus 30 [18–61] days, P < 0.001).The same was observed for 
any CMV infection (46 of 71, 65% and 76 of 189, 40%, P 
< 0.001; 138 [56–239] versus 32 [19–66] days, P < 0.001). 
The follow-up of mismatch patients was not longer than 
the rest of the study population (2917 [1512–5121] ver-
sus 3613 [2161–5228] days), P = 0.14. Although the rates 
of clinically relevant CMV infection were not significantly 
different in VGCV-treated versus immunoglobulin-treated 
FIGURE 1. Cytomegalovirus (CMV) prophylactic regimens and screening protocol used throughout the study period. HTx, heart 
transplantation; PCR, polymerase chain reaction; VGCV, valganciclovir.
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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subgroup (33 of 57 patients, 58% versus 11 of 14 patients 
79%, P = 0.13), it occurred significantly later if VGCV was 
given (143 [111–239] versus 42 [39–44], P < 0.001). Out 
of the total of study population, 14 (5.4%) patients expe-
rienced 1 recurrence of any CMV infection, and 5 (1.9%) 
patients experienced 2 recurrences. Foscarnet was applied 
in 2 patients infected with VGCV-resistant strains.
In patients with clinically relevant CMV infection, 72 
(75.0%) were treated with MMF before infection occurred 
with 1500 (1000–2000) mg total daily MMF preinfection 
dose (defined as dose used on the last visit before infec-
tion). In 11 (15.3%) patients, the dose was reduced, and 
in 44 (61.1%), MMF was stopped during infection so that 
median dose was 0 (0–1000) mg. The postinfection dose 
(defined as after 2× negative PCR CMV or the last MMF 
dosage before the end point or censoring date in patients 
who did not turn negative) was 0 (0–1000) mg. At the day 
of the first positive PCR, patients with clinically relevant 
CMV infection presented the following blood count val-
ues: 6.90 (4.20 –0.52) × 109/L leukocytes with 9.70 (4.00–
18.80) % lymphocytes (0.56 [0.28–1.10] × 109/L).
By the end of follow-up, CAV was diagnosed in 149 
(57%) patients. Most patients presented mild CAV (CAV1, 
according to ISHLT). The severity of CAV classified 
according to ISHLT at the 2 screening moments is pre-
sented in Figure 3. Twenty-two (8%) patients experienced 
TABLE 1.
Characteristics of the study population (N = 260)
Variable  
Donor characteristics
 Age, y 45 (34–53)
 Males 107 (41%)
 BMI, kg/m2 24 (22–26)
Recipient characteristics
 Age at HTx, y 50 (43–58)
 Males 172 (66%)
 BMI, kg/m2 24 (22–26)
 Primary disease
  Cardiomyopathy 163 (63%)
  Ischemic heart disease 81 (31%)
  Valvular disease 5 (2%)
  Congenital 8 (3%)
  Retransplantation 3 (1%)
 PRA >10% 9 (3.5%)
Perioperative
 Urgent transplantation 98 (38%)
 Mechanical support pre-HTx 57 (22%)
 Ischemic time, min 188 (159–219)
 CVVH 40 (15%)
Immunosuppressive regimen
 Induction therapy
  ATG 237 (92%)
  Anti-CD25 6 (2%)
  OKT3 2 (1%)
  None 13 (5%)
 Tac-based therapy 222 (85%)
 CsA-based therapy 37 (14%)
 MMF 131 (50%)
 Steroids 125 (48%)
CMV-related
 Clinically relevant CMV infection 96 (37%)
  Time from transplantation, d 57 (27–146)
 CMV primary infection 49 (19%)
 CMV infection 122 (47%)
  Time from transplantation, d 52 (26 – 143)
 CMV breakthrough infection 24 (9%)
  Time from transplantation, d 62 (42–92)
Rejection episodes
 ACR ≥ 2R/AMR (first y) 114 (44%)
 Episodes of ACR ≥ 2R/AMR
  0 88 (34%)
  1 82 (32%)
  2 56 (22%)
  ≥3 30 (12%)
Comorbidities and treatment
 Hypertension 151 (58%)
 DM pre-HTx 30 (11%)
 DM post-HTx 101 (39%)
 eGFR (CKD-EPI), pre-HTx, mL/min/1.73 m2 59 (43–73)
 eGFR (CKD-EPI), 1 y post-HTx, mL/min/1.73 m2 54 (42–71)
 Kidney transplantation post-HTx 7 (3%)
 Total cholesterol at 1 y post-HTx, mmol/L 5.1 (4.3–6.0)
 LDL at 1 y post-HTx, mmol/lL 2.64 (2.23–3.60)
 Statin treatment 246 (95%)
Data are presented as count (percentage) for categorical variables, mean (SD) for continuous 
normally distributed variables, and median (25th–75th percentile for continuous nonnormally 
distributed variables). Time from transplantation for clinically relevant CMV infection defined as 
time till first CMV PCR ≥1000 IU/mL independent of symptoms or <1000 if accompanied by 
symptoms. Primary infection was defined as CMV infection (CMV PCR ≥1000 IU/mL independent 
of symptoms or <1000 IU/mL and accompanied by symptoms) in seronegative recipients.
ACR, acute cellular rejection; AMR, antibody-mediated rejection; ATG, anti-thymocyte immunoglobu-
lin; BMI, body mass index; CKD-EPI, chronic kidney disease epidemiology collaboration; CMV, cyto-
megalovirus; csA, ciclosporin A; CVVH, continuous venovenous hemofiltration; DM, diabetes mellitus; 
eGFR, estimated glomerular filtration rate based on CKD-EPI equation; HTx, heart transplantation; 
LDL, low-density lipoprotein; MMF, mycophenolate mofetil; OKT3, monoclonal anti-human T lym-
phocyte antibody; PCR, polymerase chain reaction; PRA, panel reactive antibodies; Tac, tacrolimus.
FIGURE 2. CMV serological status at heart transplantation.  CMV, 
cytomegalovirus; D, donor; R, recipient.
FIGURE 3. Cardiac allograft vasculopathy (CAV) prevalence at 
1-y and 4-y posttransplant. Grading, according to International 
Society for Heart and Lung Transplantation (ISHLT). Figure 
presents only patients who completed 4-y follow-up (n = 218).
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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acute coronary syndrome. Among the study population, 
64 (25%) patients died during the follow-up time mostly 
due to malignancy (n  =  14, 22%), followed by CAV-
related deaths (n = 13 [20%]; see Figure 4). The temporal 
trends for CAV and various causes of death are presented 
in Figure 5 (stratified according to the presence of break-
through infection), with CAV being the major early com-
plication and malignancies contributing to mortality in the 
late post-HTx period.
Univariable regression analysis showed that neither 
CMV serological status of D and R at transplantation (D+/
R−, D+/R+, D−/R+, D−/R−) nor the occurrence of clinically 
relevant CMV infection nor CMV infection were associ-
ated with CAV (Table 2). However, we observed that out 
of 71 CMV mismatched patients (D+/R−), 24 experienced a 
breakthrough CMV infection (34%). These breakthroughs 
occurred more frequently in patients from immunoglobulin 
prophylaxis group (n = 9, 64%) than in VGCV prophylaxis 
group (n = 15, 26%), P = 0.01 (Table S3, SDC, http://links.
lww.com/TP/B827). CMV breakthroughs increased the risk 
of CAV when analyzed both univariably and multivariably 
(cause-specific hazard ratio, cause-specific hazard ratio, 95% 
[confidence interval]: 1.94 [1.11-3.40], P = 0.02), as demon-
strated in Tables 2 and 3. After excluding immunoglobulin-
treated patients from the analysis (n = 246), there was still 
a trend towards higher risk of CAV in patients with CMV 
breakthrough infection among patients on VGCV prophy-
laxis by univariable analysis (1.85 [0.96-3.53], P = 0.06), 
although the association did not persist in multivariable 
analysis (Table S4, SDC, http://links.lww.com/TP/B827). 
Other factors, that were independent predictors of CAV in 
multivariable analysis were the number of acute rejection 
(AR) episodes (1.15 [1.01-1.30], P = 0.03) and hypertension 
(1.75 [1.21-2.53], P = 0.003), whereas the use of MMF as 
maintenance immunosuppression was associated with lower 
risk of CAV (0.68 [0.48-0.98], P = 0.04). CAV-free survival 
stratified by CMV-related factors: clinically relevant CMV 
infection, CMV infection, and CMV breakthrough infection 
is presented in Figure 6. CAV-free survival according to the 
other 3 significant predictors (rejection episodes, hyperten-
sion, and MMF) is presented in Figure 7.
Rejection episodes (of grade 2R or more) occurred with 
similar frequency in patients in whom clinically relevant 
CMV infection was diagnosed (1 [0–2] versus 1 [0–2], 
P  =  0.93) compared with the rest of the study group. 
Neither were they more frequent in patients with any 
FIGURE 4. Causes of death (n = 64). CAV, cardiac allograft 
vasculopathy; MOF, multiorgan failure.
FIGURE 5. Cumulative incidence curves for major complications: combined endpoint cardiac allograft vasculopathy (CAV) grade 1 or 
higher and CAV-related death in comparison with death from other causes. CMV, cytomegalovirus.
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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CMV infection (1 [0–2] versus 1 [0–2], P = 76) nor CMV 
breakthrough (1 [0–2] versus 1 [0–2], P  =  0.75). In 19 
(19.8%) patients with clinically relevant CMV, infection 
followed the diagnosis and treatment of AR. In 8 patients, 
the rejection continued during the treatment of infection, 
and in 13 (13.5%) patients, AR was newly diagnosed dur-
ing the treatment of infection. Among CMV mismatch 
patients, 27 (38.0%) experienced rejection during VGCV 
TABLE 2.
Univariable regression analysis of combined composite endpoint consisting of first manifestation of CAV grade 1 or 
higher according to ISHLT 2010 nomenclature, elective PCI or ACS or CAV-associated death
Covariate CSHR (95% CI) P
Donor characteristics
 Age (per y) 1.01 (1.00-1.03) 0.02
 Sex (female) 0.73 (0.52-1.00) 0.05
 BMI, kg/m2 2.85 (1.32-6.14) 0.008
Recipient characteristics   
 Age at HTx (per y) 1.00 (0.99-1.02) 0.27
 Sex (female) 0.79 (0.56-1.12) 0.19
 BMI (kg/m2) 1.05 (1.00-1.09) 0.02
 PRA >10% 0.73 (0.27-1.99) 0.73
Perioperative/procedural
 Mechanical support pre-HTx 0.89 (0.60-1.32) 0.59
 Ischemic time, min 1.24 (0.78-1.98) 0.36
 Rethoracotomy (count) 1.16 (0.90-1.49) 0.23
 ICU hospitalization/stay, d 0.98 (0.97-1.00) 0.12
 CVVH post-operatively 0.87 (0.53-1.42) 0.57
Immunosuppressive regimen
 Induction: ATG 0.82 (0.42-1.63) 0.59
 Induction: anti-CD25 0.99 (0.30-3.23) 0.99
 Induction: OKT3 0.66 (0.08-5.25) 0.69
 Tac-based therapy 0.80 (0.52-1.21) 0.27
 CsA-based therapy 1.26 (0.83-1.94) 0.27
 MMF 0.63 (0.46-0.88) 0.007
CMV-related
 CMV recipient status (R+) 1.00 (0.72-1.38) 0.99
 Clinically relevant CMV infection 1.01 (0.73-1.40) 0.96
 Primary infection 1.05 (0.70-1.59) 0.80
 CMV infection 0.97 (0.70-1.35) 0.88
 Time untill infection from HTx, d 1.00 (1.00-1.003) 0.05
 CMV breakthrough 1.94 (1.18-3.18) 0.009
 Duration of clinically relevant CMV infection 1.00 (0.99-1.003) 0.14
 Prophylaxis scheme (VGCV) 0.66 (0.35-1.23) 0.19
 Number of recurrences 0.98 (0.61-1.58) 0.93
Rejection episodes
 ACR≥2R/AMR in the first-y post-HTx 1.43 (1.03-2.00) 0.03
 Episodes of ACR ≥2R/AMR (first y) 1.18 (1.01-1.39) 0.04
 Time till first ACR≥2R/AMR episode, d 1 (0.99-1.00) 0.42
 Episodes of ACR ≥2R/AMR (total) 1.13 (1.00-1.27) 0.04
Comorbidities and treatment
 Hypertension 1.66 (1.18-2.34) 0.003
 DM pre-HTx 1.21 (0.74-1.98) 0.45
 DM post-HTx 0.86 (0.62-1.20) 0.38
 eGFR (CKD-EPI), pre-HTx, mL/min/1.73 m2 1.00 (0.99-1.01) 0.61
 Kidney transplantation 1.63 (0.67-3.99) 0.28
 Total cholesterol at 1 y post-HTx (mmol/L) 1.16 (1.03-1.30) 0.02
 Statin treatment 1.10 (0.52-2.40) 0.79
CSHR for Ischemic time and time till reactivation are presented per log
2
 changes. - CSHR for other variables is presented per 1 unit of increase. The duration of clinically relevant infection was defined 
as number of days between the first positive and first negative CMV PCR. Clinically relevant CMV infection, CMV infection and CMV breakthrough infection were analyzed as time-dependent variables.
ACR, acute cellular rejection; ACS, acute coronary syndrome; AMR, antibody-mediated rejection; ATG, antithymocyte immunoglobulin; BMI, body mass index; CAV, cardiac allograft vasculopathy; CI, 
confidence interval; CKD-EPI, chronic kidney disease epidemiology collaboration; CMV, cytomegalovirus; csA, ciclosporin A; CSHR, cause-specific hazard ratio; CVVH, continuous venovenous hemofiltra-
tion; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate based on CKD-EPI equation; HTx, heart transplantation; ICU, intensive care unit; ISHLT, International Society for Heart and Lung 
Transplantation; MMF, mycophenolate mofetil; OKT3, monoclonal antihuman T lymphocyte antibody; PCI, percutaneous coronary intervention; PCR, polymerase chain reaction; PRA, panel reactive 
antibodies; R, recipient; Tac, tacrolimus; VGCV, valganciclovir.
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prophylaxis. Rejection rate did not differ significantly 
between patients on prophylaxis with VGCV (7, 50.0%) 
versus immunoglobulin (20, 35.1%), P = 0.36. The tem-
poral trend in rejection related-death and other posttrans-
plant complications with regard to the type of prophylaxis 
are presented in Figure S1 (SDC, http://links.lww.com/TP/
B827). Rejection episodes occurred with similar frequency 
in patients with CMV infection independently of change 
in MMF dosage during infection (median [IQR] rejection 
episodes: 1 [0–2] if MMF dosage maintained, 2 [1–3] if 
halved, 1 [0–2] if stopped, P = 0.22).
DISCUSSION
To the best of our best knowledge, this is the first study 
in HTx patients in the contemporary immunosuppres-
sive and antiviral prophylactic era of the new millennium, 
showing that there is no association between CMV infec-
tion and development of CAV in HTx patients. The only 
exception is the patients in whom infection occurred dur-
ing prophylactic treatment, that is, CMV breakthrough 
infection, who present significantly higher risk of CAV. AR 
and hypertension are associated significantly with CAV, 
whereas treatment with MMF reduces that risk.
The results of our study are only partially in concord-
ance with previous retrospective studies with long-term 
follow-up by Delgado et al9 or Johansson et al,8 on this 
topic with the largest sample sizes to date (N = 166 and 
N = 226 respectively). They reported a significant associa-
tion between CMV disease, infection and asymptomatic 
infection, and CAV over long-term follow-up. These stud-
ies presented different approaches towards CMV screen-
ing and prophylaxis than is maintained in our institution 
and is the current standard of care for HTx Rs. Johansson 
et al8 described a cohort of patients, the majority of whom 
were not subjected to CMV prophylaxis, which was intro-
duced only in the last 2 years of the 12-years long study 
period and which comprised oral ganciclovir for 14 weeks. 
Delgado et al9 included patients with universal prophy-
laxis, but only within the first 14 days, whereas current 
guidelines recommend 3 to 6 months ganciclovir or VGCV 
prophylaxis in high-risk patients (D+/R−) so this approach 
could not prevent CMV infection and disease in the first 
months post-HTx. Such a strategy was probably the cause 
of higher rate of CMV infection (defined by the authors as 
a positive phosphoprotein 65 antigenemia) compared with 
our study (75%–89% versus 47%). On the other hand, the 
rate of symptomatic CMV infection and disease described 
Johansson et al8 was similar to the prevalence of clinically 
relevant CMV infection in our cohort (36% versus 42%, 
respectively). However, it should be taken into account that 
our patients were subjected to CMV screening with a more 
sensitive method (quantitative real-time PCR) compared 
to the above mentioned reports (phosphoprotein 65 anti-
genemia9 and posttransplant seroconversion, virus culture, 
and qualitative CMV DNA PCR8), which could contrib-
ute to prompt detection, earlier treatment initiation, and 
continuation until there is no more active replication, 
which could decrease overall CMV burden in our study 
patients.19 It should be noticed that more potent mainte-
nance immunosuppression was applied in our center, with 
the use of MMF in half of our study population, a higher 
proportion than in previous studies (0%–22%).8,9
However, one should be aware that there are patients 
who experience CMV infection during prophylaxis, 
which increased the risk of CAV in multivariable analysis 
by 94%. These patients comprise 34% of the CMV mis-
match (D+/R−) patients within our study population, and 
the rate of CMV breakthrough on VGCV is high (26%). 
The rate of unsuccessful prophylaxis is higher than in 
renal transplant Rs treated with both standard (900 mg/d 
for 6 months) and reduced (450 mg/d for 6 months) dose 
of VGCV—2% and 13%, respectively20 as well as lung 
transplant Rs (900 mg/d, for longer than 6 months in 86% 
of patients)—9%.21 This could be influenced by higher 
immunosuppression applied for HTx compared with renal 
transplantation and shorter period of VGCV prophylaxis 
compared with both groups. Unfortunately, CMV break-
throughs among HTx Rs were not investigated before. We 
cannot exclude that these patients might have been predis-
posed to CMV infection by other concomitant infection, 
increased immunosuppression for treatment of rejection, 
drug malabsorption, nonadherence to prophylaxis, or a 
combination of the above. A larger cohort of patients with 
CMV mismatch is required to verify this association as 
well as to evaluate the efficacy of VGCV and other CMV 
antivirals and to determine the optimum timespan, dosage, 
and drug level monitoring for VGCV prophylaxis. Further 
investigation is warranted to identify patients who could 
benefit from CMV-specific immunity evaluation.
Based on the results of multivariable analysis, the num-
ber of AR episodes (both cellular and antibody-mediated 
taken together) was associated with higher risk of CAV. 
This association was mentioned in previous clinical stud-
ies,22,23 also those with the application of near-infrared 
spectroscopy, intravascular ultrasound (IVUS) imaging, or 
optical coherence tomography.24-26 The involvement of the 
immune system in the development of coronary lesions in 
HTx Rs is also supported by the data on increased immune 
system activity in CAV positive patients27 and histopatho-
logical evidence.28-30 The negative impact of rejections 
stays in accordance with a positive influence of MMF 
exerted on the risk of CAV observed in our study popula-
tion. However, the design of our study does not allow to 
draw the definitive conclusion on role of MMF in reduc-
ing the risk of CAV. The efficacy of MMF in CAV preven-
tion was analyzed in only one prospective study to date, in 
which de novo treatment with low-dose tacrolimus/siroli-
mus (n = 61) was compared to full-dose tacrolimus/MMF 
(n = 64) in HTx Rs. No significant benefit was observed 
TABLE 3.
Multivariable analysis of CAV any grade
Covariate CSHR (95% CI) P
Donor BMI, kg/m2 1.01 (0.98-1.08) 0.18
Donor age, y 1.01 (1.00-1.02) 0.10
Recipient BMI, kg/m2 1.03 (0.98-1.08) 0.19
CMV breakthrough 1.94 (1.11-3.40) 0.02
Number of ACR≥2R/AMR episodes 1.18 (1.04-1.34) 0.01
Hypertension 1.61 (1.11-2.34) 0.01
MMF 0.68 (0.47-0.97) 0.03
Total cholesterol at 1 y (mmol/L) 1.08 (0.95-1.23) 0.21
ACR, acute cellular rejection, AMR, antibody-mediated rejection, BMI, body mass index, CAV, car-
diac allograft vasculopathy; CI, confidence interval; CMV, cytomegalovirus; CSHR, cause-specific 
hazard ratio; MMF, mycophenolate mofetil.
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for any of the 2 treatment regimens.31 Taking into account 
relatively small sample size of the study by Guethoff et 
al, 31 more prospective randomized trials are necessary to 
evaluate the potential benefit of immunosuppression in 
preventing the development of CAV.
Among nonimmunologic risk factors, we have observed 
a positive association between hypertension and CAV. 
Hypertension contributes to vascular endothelial inflam-
mation and was mentioned as a risk factors by other stud-
ies.32 No impact of diabetes or total cholesterol level was 
FIGURE 6. Cardiac allograft vasculopathy (CAV)-free survival curves—cytomegalovirus (CMV)-related factors: (A) clinically relevant 
CMV infection (CRCI), (B) CMV infection, (C) CMV breakthrough infection (CB). CMV denotes any CMV infection.
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observed in multivariable model, although both D and 
R BMI as well as total cholesterol level were significant 
at univariable analysis. The results might be influenced 
by protective effect exerted by very high rate of treat-
ment with pravastatin (95%) in our study cohort, which 
is the standard approach, based on our knowledge that 
statins diminish the rate of CAV progression and patient 
survival.33,34
The main limitation of the study is heterogeneity with 
regard to type and duration of prophylaxis. Although most 
FIGURE 7. Cardiac allograft vasculopathy (CAV)-free survival curves for statistically significant factors: (A) number of rejection episodes, 
(B) mycophenolate mofetil (MMF) treatment, (C) hypertension (HTN).
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of the patients were treated with VGCV (80%), still longer 
follow-up with uniformly treated group and larger num-
bers of CMV mismatch patients are required.
Based on the results of our study, we could identify clini-
cally relevant concepts worth further investigation. First, it 
is necessary to maintain a balance between overimmunosup-
pression and underimmunosuppression, with CMV infection 
and AR s being the consequences of these states and, at the 
same time, factors predisposing for CAV. There is a need for 
a tool to evaluate the level of immunosuppression, which 
has not been fulfilled to date. Second, there is a group of 
patients at increased risk of CMV, for instance, patients who 
experience a breakthrough infection, who may benefit from 
more aggressive prophylaxis. Based on our results, immu-
noglobulins proved less effective than VGCV in preventing 
such breakthrough infection episodes. However, a combined 
therapy with VGCV and CMVIG could improve the efficacy 
of anti-CMV prophylaxis in selected patients (although selec-
tion of these patients may still pose a challenge). To date, no 
randomized direct comparison of CMVIG versus CMVIG 
plus VGCV has been performed. In a retrospective analy-
sis, Snydman et al35 did not observe significant difference in 
mortality compared with antiviral monotherapy. However, 
there is interesting data from an IVUS retrospective analysis 
by Valantine et al36 which show benefits for the addition of 
CMVIG, as well as encouraging data that show lower CMV 
DNA titers in D+/R− patients after a combined CMVIG + 
ganciclovir prophylaxis followed by 6 weeks VGCV com-
pared with R+ patients, together with lesser extent of CAV 
measured by IVUS in this subgroup.37,38 CMVIG could 
also be an additional option for those subjected to potent 
immunosuppression during rejection episodes.39 Especially 
that >20% patients with clinically relevant CMV infection 
required concomitant treatment against AR and CMVIG 
was reported to provide additional benefit in the form 
of reduced rejection rates, an effect probably related to 
CMVIG immunomodulatory effects.38
In conclusion, in the era of contemporary immuno-
suppression and VGCV prophylaxis, a significant effect 
of CMV infection on the risk of CAV was observed only 
among HTx Rs with breakthrough CMV infection during 
anti-CMV prophylaxis. Further studies are warranted to 
evaluate the efficacy, dosage, and optimal timespan of cur-
rently applied anti-CMV VGCV prophylaxis.
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